Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven drug discovery company, will present at the Asia Summit on Global Health happening May 17-18 in Hong Kong and online. Dr. Zhavoronkov will present virtually May 18, 11:30am HKT, as a part of a panel called “Ageing Well: Breakthroughs and Investment Landscape in Longevity.”
Credit: Insilico Medicine
Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven drug discovery company, will present at the Asia Summit on Global Health happening May 17-18 in Hong Kong and online. Dr. Zhavoronkov will present virtually May 18, 11:30am HKT, as a part of a panel called “Ageing Well: Breakthroughs and Investment Landscape in Longevity.”
Dr. Zhavoronkov is an expert in generative biology and chemistry as well as in aging and longevity research, and is one of the cofounders of the Aging Research and Drug Discovery conference, now in its 10th year. He first published studies on biomarkers of aging using advanced bioinformatics methods in 2014, and then trained deep neural networks (DNNs) on human “multi-omics” longitudinal data and retrained them on diseases, generating massive synthetic data with age as a generation condition.
The Company’s end-to-end Pharma.AI platform includes target identification (PandaOmics), drug design (Chemistry42), and clinical trial outcome prediction (InClinico) and has produced two drugs that have reached clinical trials. Insilico’s lead drug for the devastating chronic lung disease idiopathic pulmonary fibrosis will soon be entering Phase 2 trials with patients and its drug for COVID-19 and related variants has been approved for clinical trials and has a number of design advantages over existing COVID-19 drugs.
There are 31 drugs in Insilico’s pipeline available for partnering and licensing for indications including cancer, fibrosis, and central nervous system diseases, and the Company has partnered with leading pharma companies, including Fosun Pharma and Sanofi, to advance their programs.
About Insilico Medicine
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, connects biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system (CNS) diseases, and aging-related diseases.
For more information, visit www.insilico.co
